Strengths of this study include the concomitant measurement of three appetite- and obesity-related hormones, the use of validated antibodies to confirm LEAP2 expression, and a relatively large patient cohort for a rare tumor, which enabled meaningful analyses in this distinctive disease model. Here, LEAP2 is linked to obesity due to melanocortin 4 receptor deficiency.